ReviewBiomedicines2021
Special delEVery: Extracellular Vesicles as Promising Delivery Platform to the Brain.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- How is Nanoarchitectonics Shaping Extracellular Vesicle Research?Advanced healthcare materials · 2026Review
- Advances in microbial extracellular vesicles: synthetic biology platforms and medical applications.Extracellular vesicles and circulating nucleic acids · 2026Review
- Extracellular vesicle-mediated immunomodulation and targeted delivery: breakthroughs and challenges in rheumatoid arthritis therapy.Frontiers in immunology · 2026Review
- Neuroangiogenesis potential of mesenchymal stem cell extracellular vesicles in ischemic stroke conditions.Cell communication and signaling : CCS · 2025Review
- Extracellular Vesicles as Tools for Crossing the Blood-Brain Barrier to Treat Lysosomal Storage Diseases.Life (Basel, Switzerland) · 2025Review
- Estimating progression of Alzheimer's disease with extracellular vesicle-related multi-omics risk models.Frontiers in aging neuroscience · 2025Article
- Reproducibility and transparency: why following MISEV guidelines is beneficial for the studies on EVs and brain barriers.Extracellular vesicles and circulating nucleic acids · 2025Article
- Recent Advances in Plant-Derived Extracellular Vesicles as Nanoparticles for Cancer Drug Delivery.International journal of nanomedicine · 2025Review
- Engineered EVs designed to target diseases of the CNS.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Extracellular Vesicles as Therapeutic Resources in the Clinical Environment.International journal of molecular sciences · 2023Review
- Intranasally administered extracellular vesicles from human induced pluripotent stem cell-derived neural stem cells quickly incorporate into neurons and microglia in 5xFAD mice.Frontiers in aging neuroscience · 2023Article
- Transnasal targeted delivery of therapeutics in central nervous system diseases: a narrative review.Frontiers in neuroscience · 2023Review
- Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer's disease.Advanced drug delivery reviews · 2022Review
- Pharmacokinetics and biodistribution of extracellular vesicles administered intravenously and intranasally toJournal of extracellular biology · 2022Article
- Human Epidural AD-MSC Exosomes Improve Function Recovery after Spinal Cord Injury in Rats.Biomedicines · 2022Article
- Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders.Frontiers in immunology · 2022Review
- Extracellular vesicles: A new paradigm in understanding, diagnosing and treating neurodegenerative disease.Frontiers in aging neuroscience · 2022Review
- Stem cell-derived extracellular vesicle therapy for acute brain insults and neurodegenerative diseases.BMB reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The treatment of central nervous system (CNS) pathologies is severely hampered by the presence of tightly regulated CNS barriers that restrict drug delivery to the brain. An increasing amount of data suggests that extracellular vesicles (EVs), i.e., membrane derived vesicles that inherently protect and transfer biological cargoes between cells, naturally cross the CNS barriers. Moreover, EVs can be engineered with targeting ligands to obtain enriched tissue targeting and delivery capacities. In this review, we provide a detailed overview of the literature describing a natural and engineered CNS targeting and therapeutic efficiency of different cell type derived EVs. Hereby, we specifically focus on peripheral administration routes in a broad range of CNS diseases. Furthermore, we underline the potential of research aimed at elucidating the vesicular transport mechanisms across the different CNS barriers. Finally, we elaborate on the practical considerations towards the application of EVs as a brain drug delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.